New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
16:34 EDTWXWuXi PharmaTech reports Q3 adjusted EPS 36c, consensus 30c
Reports Q3 revenue $125.8M, consensus $123.18M.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
05:21 EDTWXWuXi PharmaTech announces holders approval of merger agreement
WuXi PharmaTech announced that at an extraordinary general meeting of shareholders, the company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger dated as of August 14, and amended on October 20 and November 20, with New WuXi Life Science and WuXi Merger Limited, a wholly owned subsidiary of Parent, pursuant to which Merger Sub will be merged with and into the company with the company surviving as a wholly owned subsidiary of Parent, and to authorize and approve any and all transactions contemplated by the Merger Agreement, including the Merger. The parties currently expect to complete the Merger next month, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. If and when completed, the Merger would result in the company becoming a privately held company, and its ADSs would no longer be listed on the New York Stock Exchange.
November 20, 2015
07:57 EDTWXWuXi PharmaTech to host special shareholder meeting
Subscribe for More Information
November 12, 2015
05:46 EDTWXWuXi NextCODE contracts with Genomics England
Genomics England has announced that it has contracted with WuXi NextCODE as a Clinical Interpretation Partner for the 100,000 Genomes Project. The China, US and Iceland-based company is the first to work with them on cancer samples and will also interpret samples in rare disease. Genomics England will work with the clinical interpretation partners to drive up the quality of interpretation of genomic data. This will lead to better understanding of disease and more personalised care for patients in the future.
November 11, 2015
12:03 EDTWXWuXi PharmaTech says ISS, Glass Lewis recommend votes for 'go-private' deal
WuXi PharmaTech announced that Institutional Shareholder Services and Glass Lewis have recommended that WuXi shareholders vote in favor of the proposal to approve the company's previously announced agreement and plan of merger pursuant to which Parent will acquire the company for $5.75 per ordinary share, or $46 per American depositary share. The company's extraordinary general meeting of shareholders to consider and vote on, among other things, the merger agreement and the transactions contemplated thereby, including the merger, will be held on November 25.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use